| Literature DB >> 20813327 |
Korcan Demir1, Tolga Unuvar, Sanem Eren, Ayhan Abaci, Ece Bober.
Abstract
BACKGROUND: Juvenile breast hypertrophy is uncommon and is characterized by excessive breast enlargement in the peripubertal period. The clinical entity is thought to result from increased sensitivity of mammary tissue to normal levels of circulating hormones. CASE: Here, we report a female patient, aged 12 years and 6 months, suffering from juvenile breast hypertrophy, who presented at the third month of symptoms and benefited from tamoxifen treatment. COMMENTS: In experienced clinics, use of tamoxifen in the treatment of juvenile breast hypertrophy during the brisk growth period may become a medical alternative to reconstructive surgery. Copyright 2010 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20813327 DOI： 10.1016/j.jpag.2009.11.003
Source DB: PubMed Journal: J Pediatr Adolesc Gynecol ISSN： 1083-3188 Impact factor: 1.814